norfloxacin has been researched along with Acute-On-Chronic Liver Failure in 2 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Acute-On-Chronic Liver Failure: Sudden liver failure in the presence of underlying compensated chronic LIVER DISEASE (e.g., LIVER CIRRHOSIS; HEPATITIS; and liver injury and failure) due to a precipitating acute hepatic insult.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to evaluate the role of prophylactic norfloxacin in preventing bacterial infections and its effect on transplant-free survival (TFS) in patients with acute-on-chronic liver failure (ACLF) identified by the Asian Pacific Association for the Study of the Liver criteria." | 9.51 | Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial. ( Fatima, S; Gora, BA; Gujjarlapudi, D; Gupta, R; Kulkarni, AV; Kumar, K; Premkumar, M; Rao, PN; Rapole, B; Reddy, DN; Sasikala, M; Sharma, M; Simhadri, V; Tirumalle, S; Yelamanchili, S, 2022) |
| "This study aimed to evaluate the role of prophylactic norfloxacin in preventing bacterial infections and its effect on transplant-free survival (TFS) in patients with acute-on-chronic liver failure (ACLF) identified by the Asian Pacific Association for the Study of the Liver criteria." | 5.51 | Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial. ( Fatima, S; Gora, BA; Gujjarlapudi, D; Gupta, R; Kulkarni, AV; Kumar, K; Premkumar, M; Rao, PN; Rapole, B; Reddy, DN; Sasikala, M; Sharma, M; Simhadri, V; Tirumalle, S; Yelamanchili, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kulkarni, AV | 1 |
| Tirumalle, S | 1 |
| Premkumar, M | 1 |
| Kumar, K | 1 |
| Fatima, S | 1 |
| Rapole, B | 1 |
| Simhadri, V | 1 |
| Gora, BA | 1 |
| Sasikala, M | 1 |
| Gujjarlapudi, D | 1 |
| Yelamanchili, S | 1 |
| Sharma, M | 1 |
| Gupta, R | 1 |
| Rao, PN | 1 |
| Reddy, DN | 1 |
| Crocombe, D | 1 |
| Freemantle, N | 1 |
| O'Brien, A | 1 |
1 trial available for norfloxacin and Acute-On-Chronic Liver Failure
| Article | Year |
|---|---|
Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial.
Topics: Acute-On-Chronic Liver Failure; Bacterial Infections; Double-Blind Method; Humans; Liver Cirrhosis; | 2022 |
1 other study available for norfloxacin and Acute-On-Chronic Liver Failure
| Article | Year |
|---|---|
Additional Analyses for the Published Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure.
Topics: Acute-On-Chronic Liver Failure; Humans; Liver Cirrhosis; Norfloxacin | 2022 |